Visanne (dienogest) / Mochida, Bayer - LARVOL DELTA

The Effect of Dienogest on Deep Endometriosis Nodules Involving the Recto-Sigmoid Colon: A Prospective Longitudinal Long-Term Study. (PubMed, J Clin Med) - " Long-term Dienogest therapy significantly relieves clinical symptoms related to recto-sigmoid DE. This is accompanied by a significant reduction in the lesion volume but not the maximum lesion diameter."

Journal • Endometriosis • Gynecology • Women's Health

Dienogest use and the risk of breast and gynecologic cancers: A nationwide population-based study. (PubMed, Int J Gynaecol Obstet) - "Dienogest use in women with endometriosis was not associated with higher or lower risks of breast, endometrial, or tubo-ovarian cancer compared with GnRH agonists, supporting its oncologic safety. Further longer-term studies are warranted to clarify duration-specific effects."

Journal • Breast Cancer • Endometrial Cancer • Endometriosis • Gynecologic Cancers • Gynecology • Oncology • Ovarian Cancer • Solid Tumor • Women's Health

Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study. (PubMed, Reprod Biomed Online) - "Patients with adenomyosis with more severe dysmenorrhoea and HMB may benefit most from dienogest treatment, but also face higher recurrence risk if the treatment is discontinued, especially when their lesions are highly fibrotic. Therefore, only patients with severe dysmenorrhoea, severe HMB and higher lesional stiffness may require long-term medication, whereas others may take a break from daily medications."

Journal • Endometriosis • Fibrosis • Gynecology • Uterine Leiomyoma • Women's Health

Vaginal Contraception with NuvaRing@ Decreases Symptoms and Uterine Features of Adenomyosis. A Prospective Evaluation. (PubMed, Contraception) - "In women with adenomyosis contraception with NuvaRing@ is useful and can be proposed because it reduces the clinical signs and the uterine ultrasound features of adenomyosis."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Risk factors and countermeasures for abnormal uterine bleeding during dienogest therapy for adenomyosis: a review. (PubMed, Front Reprod Health) - "Adenomyosis, an estrogen-dependent disorder, requires long-term therapy as current treatments (GnRH agonists, danazol, etc.) show symptom recurrence post-discontinuation. Dienogest (DNG), a selective progesterone receptor agonist, effectively reduces adenomyosis-related pain but causes abnormal uterine bleeding (AUB) in some patients, likely due to pseudodecidual breakthrough bleeding, significantly impacting treatment compliance. This review examines risk factors for DNG-associated AUB and advances in management strategies to improve patient adherence during prolonged therapy."

Journal • Review • Endometriosis • Pain • Women's Health

Stress-Induced Hyperprolactinemia Mimicking Pituitary Pathology: A Diagnostic Challenge. (PubMed, Cureus) - "We present the case of a 37-year-old non-pregnant female with a known history of ovarian endometriosis, diagnosed more than a decade ago and currently managed with dienogest 2 mg daily...This case underscores the diagnostic complexity of endocrine abnormalities when neuro-ophthalmologic symptoms are present without radiologic findings. It highlights the importance of considering psychological stress as a potential contributor and reinforces the need for a holistic, multidisciplinary approach to avoid overdiagnosis and ensure appropriate management."

Journal • Acne Vulgaris • Endocrine Disorders • Endometriosis • Gynecology • Ophthalmology • Pain • Pituitary Gland Carcinoma • Retinal Disorders • Women's Health • PRL

Onset and recovery from depressive mood changes on progestin treatment - a case series reporting the course and type of depressive symptoms in progestin users with different histories and risks. (PubMed, Eur J Contracept Reprod Health Care) - "Seven women reported depressive symptoms after newstart with desogestrel, dienogest or the LNG-IUS 52 mg. It is promising that symptoms resolved within few weeks after discontinuation. Close follow-up of all newstarters is recommended."

Journal • CNS Disorders • Depression • Endometriosis • Gynecology • Psychiatry • Women's Health

Hormonal imbalance-mediated immune inflammation in endometrial decidualization disorder. (PubMed, Placenta) - "Dienogest suppresses aromatase/cyclooxygenase-2 (COX-2)-mediated oestrogen synthesis and restores progesterone sensitivity via PR-B upregulation. Immunomodulatory approaches, including corticosteroids and tumour necrosis factor-α inhibitors, improve pregnancy outcomes in endometriosis-associated infertility. Future research, leveraging state-of-the-art technologies, should prioritise elucidating the molecular interactions within the oestrogen-progesterone-immune axis and translating these insights into personalised therapies to optimise the management of decidualization-related disorders."

Journal • Review • Endometriosis • Gynecology • Infertility • Inflammation • Oncology • Sexual Disorders • Women's Health • IL10 • PGR

Deeply Infiltrating Endometriosis (DIE) No More: Dienogest as a Game Changer in Rectovaginal Endometriosis. (PubMed, Cureus) - "This is the first reported case of Dienogest successfully shrinking rectovaginal deeply infiltrating endometriosis from 3 cm to undetectable on ultrasound and vaginal examination. This case demonstrates the success of Dienogest as a therapeutic modality for rectovaginal endometriosis, highlighting its promising potential as a standard treatment approach in the long-term management of the relapsing, chronic, and debilitating nature of endometriosis."

Journal • Endometriosis • Gynecology • Women's Health

Association between depressive symptoms and dienogest in patients treated for endometriosis: Using the Center for Epidemiological Studies Depression (CES-D) and the State-Trait Anxiety Inventory (STAI). (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Dienogest treatment was associated with clinically significant depressive symptoms in over one-third of patients, underscoring the need for mental health screening during therapy."

Journal • CNS Disorders • Depression • Endometriosis • Gynecology • Mood Disorders • Pain • Psychiatry • Women's Health

Navigating Complexity: Advanced Visualization for Müllerian Anomalies and its implications for diagnoses and surgical planning. (PubMed, J Pediatr Adolesc Gynecol) - "Post-operative VR reconstruction of pre-operative MRI demonstrated tangible educational and planning value. Routine prospective VR adoption for complex Müllerian anomalies may optimize counselling, resident education, and surgical safety."

Journal • Cardiovascular • Endometriosis • Gynecology • Heart Failure • Musculoskeletal Pain • Pain • Women's Health

Sanleng Wan inhibits endometriosis progression by regulating sphingolipid metabolism via the S1P/S1PR1-Akt axis based on serum metabolomics and network pharmacology. (PubMed, J Ethnopharmacol) - "This study, utilizing serum metabolomics and network pharmacology, demonstrates the therapeutic effects of SLW in endometriosis model rats by modulating sphingolipid metabolism via the S1P/S1PR1-Akt axis, thereby enhancing understanding of its underlying mechanisms of action."

Journal • Endometriosis • Fibrosis • Gynecology • Immunology • Infertility • Metabolic Disorders • Musculoskeletal Pain • Pain • Sexual Disorders • Transplantation • Women's Health • S1PR1 • SPHK2 • TGFB1

GnRH analogues and dienogest for second line treatment of endometriosis-associated pain: a systematic review, meta-analysis, and network meta-analysis. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Oral GnRH antagonist has shown to be the most effective in improving dysmenorrhea and NMPP, as compared to the other drugs. However, dienogest was found more beneficial in the treatment of dyspareunia. These finding may serve clinical practitioners in electing medical therapy."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

A Single-Center, Double-Arm, Randomized Controlled Clinical Study on the Treatment of Adenomyosis with Dienogest Combined with Magnetic Resonance-Guided Focused Ultrasound Ablation (ChiCTR) - P=N/A | N=76 | Not yet recruiting | Sponsor: Foshan Hospital of Traditional Chinese Medicine; Foshan Hospital of Traditional Chinese Medicine

New trial • Endometriosis • Women's Health

Do we need Placebo-Controlled Studies to Assess Medical Treatments of Pain Associated with Endometriosis? (WCE 2025) - "These included GnRh analogues, estrogen-progestin and progestin-only contraceptives, Dienogest and GnRh receptor antagonists. Data collection is nearing completion, full statistical studies are underway and will be presented at the conference. Conclusion All placebo-controlled studies have confirmed the efficacy of hormonally-induced amenorrhea in the treatment of pain associated with endometriosis, calling into question the ethical acceptability of this type of study in the evaluation of new drugs that induce amenorrhea."

Clinical • Endometriosis • Gynecology • Pain • Women's Health

Levonorgestrel Releasing Intrauterine System (LNG) versus Dienogest for the treatment of Adenomyosis (WCE 2025) - "LNG-IUS offers superior control of menstrual bleeding, more consistent pain relief, and a better overall safety profile. Dienogest may be considered as an alternative for women who prefer oral therapy ."

Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Treatment of Endometriosis – Focus on Improving Quality of Life (WCE 2025) - "The use of progestogens with affinity for receptors other than progesterone can lead to the development of side effects. In the presence of risks of endometriosis-associated complications, switching to dydrogesterone is recommended, since the presence of only a continuous regimen in dienogest limits its capabilities in terms of overcoming several undesirable effects. Group 2 patients were more likely to have endocrine and neurological diseases, which could possibly have influenced the occurrence of side effects and the need for early discontinuation of dienogest therapy."

HEOR • CNS Disorders • Depression • Endometriosis • Gynecology • Migraine • Pain • Psychiatry • Women's Health

Retroperitoneal Fibrosis: The Cause of Deep Endometriosis-Related Chronic Pelvic Pain (WCE 2025) - "Subsequent PV findings by another gynecologist reported CDS tenderness and resistance, favor pelvic endometriosis, which was treated with a 3-month GnRH agonist, followed by Dienogest...Hysterectomy alone without removal of retroperitoneal fibrosis is considered inadequate, resulting in persistent pain. Although extensive resection is effective, this mandates meticulous and expertise skills in retroperitoneal surgical dissection to achieve safe and optimal patient outcomes."

Endometriosis • Fibrosis • Gynecology • Immunology • Infertility • Inflammation • Musculoskeletal Pain • Pain • Sexual Disorders • Women's Health

Factors for Optimal Long-Term Control and Hormone-Sensitive Cancer Risks in Patients with Endometriosis: A Retrospective Cohort Study (WCE 2025) - "Medication types and dosages, including dienogest, danazol, combined oral contraceptives, levonorgestrel intrauterine device, and leuprolide were assessed. Conclusion In the Asian population, dienogest effectively reduced the need for definitive surgeries in patients with adenomyosis, but not for endometrioma, without increasing the risk of hormone- sensitive cancers and thromboembolic events. More evidence is needed from larger cohorts and long-term follow-up in populations of different ethnicities and cultures."

Retrospective data • Breast Cancer • CNS Disorders • Endometrial Cancer • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Oncology • Ovarian Cancer • Solid Tumor • Vascular Neurology • Women's Health

Dienogest Impact on DIE Lesions and Prognostic Treatment Selection Through Gene Expression and Histological Presentation (WCE 2025) - "The impact of NFKB and HSP90 inhibitors Triptolide and Luminespib on endometrial epithelial cells was validated in high content screening of organoids. Novel compounds for epithelial dominated endometriotic lesions were identified. Together this study provides a genuine pathway to stratify the current approach to endometriosis treatment."

Endometriosis • Fibrosis • Gynecology • Immunology • Women's Health • CDC37 • CXCL1 • CXCL12 • CXCR4 • PGR • SDC4

Medical treatment for adenomyosis: long term use of progestins. (PubMed, Gynecol Endocrinol) - "The treatment groups included dienogest (2 mg, n = 71), levonorgestrel-releasing intrauterine device (52 mg, n = 25), desogestrel (75 mcg, n = 20), and drospirenone (4 mg, n = 24)...Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients...Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response. Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes."

Journal • Endometriosis • Long-acting Reversible Contraceptives • Pain • Women's Health

Effects of dienogest treatment on endometrioma-related clinical symptoms and endometrioma size: retrospective cohort study. (PubMed, Front Med (Lausanne)) - "Similarly, the findings of T2 and each subsequent visit of the patients in the long-term group were compared with the initial findings and a significant reduction in endometrioma size and VAS scores was observed. Although the effectiveness of dienogest treatment for endometrioma seems to begin in the sixth month, its effectiveness maximizes in patients whose treatment duration is over 1 year."

Journal • Retrospective data • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis. (PubMed, Obstet Gynecol) - "This network meta-analysis indicates that leuprolide in combination with combined OCP, elagolix, vitamins C and E, and gestrinone may represent the most effective therapeutic options for alleviating endometriosis-associated pelvic pain, dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. These findings enhance our understanding of the relative efficacy of treatment strategies for pain associated with endometriosis. Future research should focus on conducting larger-scale and rigorously designed clinical trials within the target patient populations to further validate these results."

Journal • Retrospective data • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial. (PubMed, JMIR Res Protoc) - "This is the first trial to compare efficacy and safety between 1 mg/day and 2 mg/day of long-term dienogest use in patients with dysmenorrhea caused by endometriosis. Combining diagnostic imaging with patient questionnaires and blood tests allows the determination of efficacy against endometriosis itself."

Clinical protocol • Journal • Endometriosis • Gynecology • Pain • Women's Health

Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelines. (PubMed, Acta Obstet Gynecol Scand) - "Dienogest is comparable to COC in terms of efficacy and tolerability. The therapeutic choice should be based on the patient's preference, clinical history, and experience."

Adverse events • Journal • Retrospective data • Review • Alopecia • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health